-
1 Comment
Akoustis Technologies, Inc is currently in a long term downtrend where the price is trading 14.3% below its 200 day moving average.
From a valuation standpoint, the stock is 680.8% more expensive than other stocks from the Technology sector with a price to sales ratio of 197.3.
Akoustis Technologies, Inc's total revenue rose by 152.5% to $1M since the same quarter in the previous year.
Its net income has dropped by 27.9% to $-12M since the same quarter in the previous year.
Finally, its free cash flow fell by 17.1% to $-10M since the same quarter in the previous year.
Based on the above factors, Akoustis Technologies, Inc gets an overall score of 1/5.
| CurrencyCode | USD |
|---|---|
| Exchange | NASDAQ |
| ISIN | None |
| Sector | Healthcare |
| Industry | Biotechnology |
| Beta | nan |
|---|---|
| PE Ratio | None |
| Target Price | None |
| Market Cap | 1B |
| Dividend Yield | None |
Aktis Oncology, Inc. operates as a clinical-stage oncology company that engages in the development of targeted radiopharmaceutical therapies for cancer treatment. The company offers a miniprotein radioconjugate platform to discover and develop radiopharmaceutical therapies that deliver the tumor-killing properties of radioisotopes. It offers Nectin-4, a miniprotein radioconjugate for the treatment of locally advanced or metastatic urothelial cancer. Its products include AKY-1189 to deliver a radioisotope to Nectin-4 expressing tumors for the treatment of metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and AKY-2519 to deliver radioisotope to B7-H3 CD276 expressing tumors targeting prostate, lung and other solid tumors. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020. Aktis Oncology, Inc. was incorporated in 2020 and is based in Boston, Massachusetts.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for AKTS using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026
